HSCT

Question 1

preparative conditioning regimens

Answer 1

Myeloablative regimen - causes profound cytopenia
Reduced Intensity regimen - causes prolonged cytopenia
Non-myeloablative regimen - causes minimal cytopenia

Question 2

Autologous SCT

Answer 2

no need for HLA matching

myeloablative regimen

Question 3

Acute GVHD

Answer 3

< 3 months
skin, liver, GI tract
Immunosuppressive agents such as methotrexate, sirolimus, cyclosporine, and tacrolimus are used for prevention, and glucocorticoids and other immunosuppressive agents are used for treatment.

Question 4

HCT donor selection

Answer 4

1. Matched related donor (preferred) 6/6 HLA-A, -B, -DR sibling match
2. Matched unrelated donor: 8/8 HLA-A, -B, -C, -DR match
3. Mismatched related donor
   - haploidentical donor

Question 5

Matching

Answer 5

Matching donor and recipient for human leukocyte antigen (HLA) class I (-A, -B, -C) and class II (-DRB1 ) haplotypes.

Question 6

GVHD

Answer 6

donor-derived T cells recognize recipient antigens as foreign,
resulting in activation, expansion, and cytokine release and leading to destruction of host tissues

Question 7

mTOR inhibitors

Answer 7

sirolimus

Question 8

calcineurin inhibitors

Answer 8

tacrolimus and cyclosporine